脓疱型银屑病的生物制剂治疗
|
摘要
脓疱型银屑病是银屑病中比较严重、治疗困难、可危及患者生命的类型。目前治疗方法主要包括系统使用阿维A酸、环孢素和甲氨喋呤,以及光化学疗法和局部治疗。但一些患者对上述治疗效果不佳,最近国际上报道了一些生物制剂治疗脓疱型银屑病的临床研究。本文对这些研究进行了综述。
Pustular psoriasis is a severe subtype of psoriasis which is difficult to treat and life-threatening. Current treatments mainly include systematic use of acitretin, cyclosporine and methotrexate, as well as PUVA and topical treatment. But, some patients are resistant to treatment. Recently, biologicals for the treatment of pustular psoriasis have been reported and Those reports are reviewed in the paper.
Pustular psoriasis is a severe subtype of psoriasis which is difficult to treat and life-threatening. Current treatments mainly include systematic use of acitretin, cyclosporine and methotrexate, as well as PUVA and topical treatment. But, some patients are resistant to treatment. Recently, biologicals for the treatment of pustular psoriasis have been reported and Those reports are reviewed in the paper.
引文
[1] Carr D,Tusa MG,Carroll CL,et al.Open label trial of alefacept in palmoplantar pustular psoriasis[J].J Dermatolog Treat,2008,19(2):97-100.
[2] Wozel G,Vitez L,Meurer M.Palmoplantar pustular psoriasis:successful therapy with efalizumab after non-response to infliximab[J].Acta Dermatovenerol Alp Pannonica Adriat,2008,17(3):133-136.
[3] Matsumoto A,Komine M,Karakawa M,et al.Adalimumab administration after infliximab therapy is a successful treatment strategy for generalized pustular psoriasis[J].J Dermatol,2017,44(2):202-204.
[4] Alvarez AC,Rodríguez-Nevado I,De Argila D,et al.Recalcitrant pustular psoriasis successfully treated with adalimumab[J].Pediatr Dermatol,2011,28(2):195-197.
[5] Ibis N,Hocaoglu S,Cebicci MA,et al.Palmoplantar pustular psoriasis induced by adalimumab:a case report and literature review[J].Immunotherapy,2015,7(7):717-720.
[6] Kawakami H,Maeda T,Abe N,Matsumoto Y,et al.Efficacy of adalimumab and methotrexate combination therapy on generalized pustular psoriasis patients unresponsive to infliximab monotherapy due to anti-infliximab antibody development[J].J Dermatol,2015,42(1):94-95.
[7] Tsang V,Dvorakova V,Enright F,et al.Successful use of infliximab as first line treatment for severe childhood generalized pustular psoriasis[J].J Eur Acad Dermatol Venereol,2016,30(11):e117-e119.
[8] Fialová J,Vojá?ková N,Vaňousová D,et al.Juvenile generalized pustular psoriasis treated with etanercept[J].Dermatol Ther,2014,27(2):105-108.
[9] Floristan U,Feltes R,Ramírez P,et al.Recalcitrant palmoplantar pustular psoriasis treated with etanercept[J].Pediatr Dermatol,2011,28(3):349-350.
[10] Schnabel V,Broekaert SMC,Sch?n MP,et al.Clearance of annular pustular psoriasis with ustekinumab[J].Eur J Dermatol,2017,27(3):296-297.
[11] Schnabel V,Broekaert SMC,Sch?n MP,et al.Markham,Generalized pustular psoriasis treated with ustekinumab[J].Clin Exp Dermatol,2016,41(6):689-690.
[12] Buder V,Herberger K,Jacobi A,et al,Ustekinumab in the treatment of palmoplantar pustular psoriasis - a case series of nine patients[J].J Dtsch Dermatol Ges,2016,14(11):1108-1113.
[13] Hay RA,Pan JY.Paradoxical flare of pustular psoriasis triggered by ustekinumab,which responded to adalimumab therapy[J].Clin Exp Dermatol,2014,39(6):751-752.
[14] Sano S,Kubo H,Morishima H,et al.Guselkumab,a human interleukin-23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis:Efficacy and safety analyses of a 52-week,phase 3,multicenter,open-label study[J].J Dermatol,2018,45(5):529-539.
[15] Ho PH,Tsai TF.Successful treatment of refractory juvenile generalized pustular psoriasis with secukinumab monotherapy:A case report and review of published work[J].J Dermatol,2018,45(11):1353-1356.
[16] Dogra S,Bishnoi A,Narang T,et al.Secukinumab-induced paradoxical pustular psoriasis[J].Clin Exp Dermatol,2018,44(1):72-73.
[17] Armstrong AW,Vender R,Kircik L.Secukinumab in the treatment of palmoplantar,nail,scalp,and pustular psoriasis[J].J Clin Aesthet Dermatol,2016,9(6 Suppl 1):S12-S16.
[18] Saeki H,Nakagawa H,Nakajo K,et al.Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis,erythrodermic psoriasis and generalized pustular psoriasis:Results from a 52-week,open-label,phase 3 study (UNCOVER-J)[J].J Dermatol,2017,44(4):355-362.
[19] Wilsmann-Theis D,Schnell LM,Ralser-Isselstein V,et al.Successful treatment with interleukin-17A antagonists of generalized pustular psoriasis in patients without IL36RN mutations[J].J Dermatol,2018,45(7):850-854.
[20] Yamasaki K,Nakagawa H,Kubo Y,et al.Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma:results from a 52-week,open-label study[J].Br J Dermatol,2017,176(3):741-751.
[21] Khemis A,Cavalié M,Montaudié H,et al.Rebound pustular psoriasis after brodalumab discontinuation[J].Br J Dermatol,2016,175(5):1065-1066.
[22] Salim A,Emerson RM,Dalziel KL.Successful treatment of severe generalized pustular psoriasis with basiliximab (interleukin-2 receptor blocker)[J].Br J Dermatol,2000,143(5):1121-1122.
[23] Jeon C,Nakamura M,Sekhon S,et al.Generalized pustular psoriasis treated with apremilast in a patient with multiple medical comorbidities[J].JAAD Case Rep,2017,3(6):495-497.
[2] Wozel G,Vitez L,Meurer M.Palmoplantar pustular psoriasis:successful therapy with efalizumab after non-response to infliximab[J].Acta Dermatovenerol Alp Pannonica Adriat,2008,17(3):133-136.
[3] Matsumoto A,Komine M,Karakawa M,et al.Adalimumab administration after infliximab therapy is a successful treatment strategy for generalized pustular psoriasis[J].J Dermatol,2017,44(2):202-204.
[4] Alvarez AC,Rodríguez-Nevado I,De Argila D,et al.Recalcitrant pustular psoriasis successfully treated with adalimumab[J].Pediatr Dermatol,2011,28(2):195-197.
[5] Ibis N,Hocaoglu S,Cebicci MA,et al.Palmoplantar pustular psoriasis induced by adalimumab:a case report and literature review[J].Immunotherapy,2015,7(7):717-720.
[6] Kawakami H,Maeda T,Abe N,Matsumoto Y,et al.Efficacy of adalimumab and methotrexate combination therapy on generalized pustular psoriasis patients unresponsive to infliximab monotherapy due to anti-infliximab antibody development[J].J Dermatol,2015,42(1):94-95.
[7] Tsang V,Dvorakova V,Enright F,et al.Successful use of infliximab as first line treatment for severe childhood generalized pustular psoriasis[J].J Eur Acad Dermatol Venereol,2016,30(11):e117-e119.
[8] Fialová J,Vojá?ková N,Vaňousová D,et al.Juvenile generalized pustular psoriasis treated with etanercept[J].Dermatol Ther,2014,27(2):105-108.
[9] Floristan U,Feltes R,Ramírez P,et al.Recalcitrant palmoplantar pustular psoriasis treated with etanercept[J].Pediatr Dermatol,2011,28(3):349-350.
[10] Schnabel V,Broekaert SMC,Sch?n MP,et al.Clearance of annular pustular psoriasis with ustekinumab[J].Eur J Dermatol,2017,27(3):296-297.
[11] Schnabel V,Broekaert SMC,Sch?n MP,et al.Markham,Generalized pustular psoriasis treated with ustekinumab[J].Clin Exp Dermatol,2016,41(6):689-690.
[12] Buder V,Herberger K,Jacobi A,et al,Ustekinumab in the treatment of palmoplantar pustular psoriasis - a case series of nine patients[J].J Dtsch Dermatol Ges,2016,14(11):1108-1113.
[13] Hay RA,Pan JY.Paradoxical flare of pustular psoriasis triggered by ustekinumab,which responded to adalimumab therapy[J].Clin Exp Dermatol,2014,39(6):751-752.
[14] Sano S,Kubo H,Morishima H,et al.Guselkumab,a human interleukin-23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis:Efficacy and safety analyses of a 52-week,phase 3,multicenter,open-label study[J].J Dermatol,2018,45(5):529-539.
[15] Ho PH,Tsai TF.Successful treatment of refractory juvenile generalized pustular psoriasis with secukinumab monotherapy:A case report and review of published work[J].J Dermatol,2018,45(11):1353-1356.
[16] Dogra S,Bishnoi A,Narang T,et al.Secukinumab-induced paradoxical pustular psoriasis[J].Clin Exp Dermatol,2018,44(1):72-73.
[17] Armstrong AW,Vender R,Kircik L.Secukinumab in the treatment of palmoplantar,nail,scalp,and pustular psoriasis[J].J Clin Aesthet Dermatol,2016,9(6 Suppl 1):S12-S16.
[18] Saeki H,Nakagawa H,Nakajo K,et al.Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis,erythrodermic psoriasis and generalized pustular psoriasis:Results from a 52-week,open-label,phase 3 study (UNCOVER-J)[J].J Dermatol,2017,44(4):355-362.
[19] Wilsmann-Theis D,Schnell LM,Ralser-Isselstein V,et al.Successful treatment with interleukin-17A antagonists of generalized pustular psoriasis in patients without IL36RN mutations[J].J Dermatol,2018,45(7):850-854.
[20] Yamasaki K,Nakagawa H,Kubo Y,et al.Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma:results from a 52-week,open-label study[J].Br J Dermatol,2017,176(3):741-751.
[21] Khemis A,Cavalié M,Montaudié H,et al.Rebound pustular psoriasis after brodalumab discontinuation[J].Br J Dermatol,2016,175(5):1065-1066.
[22] Salim A,Emerson RM,Dalziel KL.Successful treatment of severe generalized pustular psoriasis with basiliximab (interleukin-2 receptor blocker)[J].Br J Dermatol,2000,143(5):1121-1122.
[23] Jeon C,Nakamura M,Sekhon S,et al.Generalized pustular psoriasis treated with apremilast in a patient with multiple medical comorbidities[J].JAAD Case Rep,2017,3(6):495-497.